Literature DB >> 4330314

In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum.

E Goldstein, M C Eagle, M L LaCasse.   

Abstract

It is an acceptable medical practice to use second-line antimycobacterial drugs in combination with isoniazid in treatment of isoniazid-resistant tuberculosis. Recent investigations have demonstrated the importance of determining chemotherapeutic interaction in instances of multiple antibiotic use. We studied the inhibitory effect of combinations of isoniazid with ethambutol, rifampin, ethionamide, cycloserine, viomycin, and kanamycin against three isoniazid-resistant strains of Mycobacterium tuberculosis and three strains of M. fortuitum. The isobologram technique with drug concentrations of 0.4 to 100 mug/ml was used. With the exception of single instances in which kanamycin plus isoniazid (M. tuberculosis strain 9999) and ethionamide plus isoniazid (M. fortuitum strain 2080) seemed to have a synergistic effect, neither synergy nor antagonism was noted for any of the combinations. These studies show that the combined use of isoniazid and a second line antimycobacterial agent results in vitro in indifferent inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4330314      PMCID: PMC376309          DOI: 10.1128/am.22.3.329-333.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  22 in total

1.  Mode of action of ethambutol on Mycobacterium tuberculosis, strain H37R V.

Authors:  N A KUCK; E A PEETS; M FORBES
Journal:  Am Rev Respir Dis       Date:  1963-06

2.  Selective inhibition of nucleic acid synthesis in Mycobacterium tuberculosis by isoniazid.

Authors:  P R GANGADHARAM; F M HAROLD; W B SCHAEFER
Journal:  Nature       Date:  1963-05-18       Impact factor: 49.962

3.  Pharmacologic and toxicologic observations on hydrazine derivatives of isonicotinic acid (rimifon, marsilid).

Authors:  W M BENSON; P L STEFKO; M D ROE
Journal:  Am Rev Tuberc       Date:  1952-04

4.  Comparative studies of cycloserine inhibition of mycobacteria.

Authors:  J E Hawkins; V R McClean
Journal:  Am Rev Respir Dis       Date:  1966-04

5.  Pseudomonas pseudomallei: susceptibility to chemotherapeutic agents.

Authors:  T C Eickhoff; J V Bennett; P S Hayes; J Feeley
Journal:  J Infect Dis       Date:  1970-02       Impact factor: 5.226

6.  Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds.

Authors:  J BERNSTEIN; W A LOTT; B A STEINBERG; H L YALE
Journal:  Am Rev Tuberc       Date:  1952-04

7.  Mode of action of ethambutol.

Authors:  M FORBES; N A KUCK; E A PEETS
Journal:  J Bacteriol       Date:  1962-11       Impact factor: 3.490

8.  In vitro effect of rifampin on mycobacteria.

Authors:  V Lorian; M Finland
Journal:  Appl Microbiol       Date:  1969-02

9.  In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa.

Authors:  T C Eickhoff
Journal:  Appl Microbiol       Date:  1969-09

10.  Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy.

Authors:  R M MCCUNE; R TOMPSETT
Journal:  J Exp Med       Date:  1956-11-01       Impact factor: 14.307

View more
  1 in total

1.  A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.

Authors:  Julian G Hurdle; Robin B Lee; Nageshwar R Budha; Elizabeth I Carson; Jianjun Qi; Michael S Scherman; Sang Hyun Cho; Michael R McNeil; Anne J Lenaerts; Scott G Franzblau; Bernd Meibohm; Richard E Lee
Journal:  J Antimicrob Chemother       Date:  2008-08-07       Impact factor: 5.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.